Meyahealth
HomeGeneticsGenePRKN gene
Back to Gene
PRKN gene
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Gene

PRKN gene

The PRKN gene provides instructions for making the protein parkin, which acts as a cellular quality control system to degrade unneeded proteins and maintain mitochondrial health.

Normal Function

The PRKN gene, one of the largest human genes, provides instructions for making a protein called parkin. Parkin plays a role in the cell machinery that breaks down (degrades) unneeded proteins by tagging damaged and excess proteins with molecules called ubiquitin. Ubiquitin serves as a signal to move unneeded proteins into specialized cell structures known as proteasomes, where the proteins are degraded. The ubiquitin-proteasome system acts as the cell's quality control system by disposing of damaged, misshapen, and excess proteins. This system also regulates the availability of proteins that are involved in several critical cell activities, such as the timing of cell division and growth. Because of its activity in the ubiquitin-proteasome system, parkin belongs to a group of proteins called E3 ubiquitin ligases.

Parkin appears to be involved in the maintenance of mitochondria, the energy-producing centers in cells. Research suggests that parkin may help trigger the destruction of mitochondria that are not working properly. Additionally, parkin may act as a tumor suppressor protein, preventing cells from growing and dividing too rapidly or in an uncontrolled way. It may also regulate the supply and release of synaptic vesicles from nerve cells, which contain chemical messengers that transmit signals between nerve cells.

Health Conditions Related to Genetic Changes

Parkinson's disease

Researchers have identified more than 200 PRKN gene mutations that cause Parkinson's disease, a condition characterized by progressive problems with movement and balance. Mutations in this gene are associated with the juvenile form of Parkinson's disease (appearing before age 20) and some cases of the late-onset form (beginning after age 50).

  • Mechanism: Mutations often lead to an abnormally small, nonfunctional parkin protein that is rapidly degraded, or they prevent the production of the protein entirely.
  • Cellular Impact: The loss of parkin activity likely disturbs the ubiquitin-proteasome system, causing unneeded proteins to accumulate. This buildup can disrupt the release of chemical messengers like dopamine.
  • Consequence: The loss of dopamine-producing nerve cells is a characteristic feature of Parkinson's disease. Mitochondrial dysfunction in these cells may also play a significant role in the disease's symptoms.

Leprosy

Common variations (polymorphisms) in the PRKN gene and the neighboring PACRG gene can increase the risk of contracting Hansen disease (leprosy), which affects the nerves and skin. Researchers believe that the ubiquitin-proteasome system may play a role in controlling the Mycobacterium leprae infection, and these polymorphisms may make the system less efficient.

Lung, Ovarian, and Other Cancers

The PRKN gene is located in a region on chromosome 6 known as FRA6E, a fragile area prone to breakage and rearrangement. In several cancers—including lung cancer, ovarian cancer, glioblastoma, and colorectal cancer—segments of the FRA6E region are abnormally deleted or duplicated.

  • These genetic changes are somatic, meaning they occur only in tumor cells and are not inherited.
  • Because parkin acts as a tumor suppressor, the resulting shortage of this protein can allow cells to grow and divide in an uncontrolled manner, leading to tumor formation.

Other Names for This Gene

  • AR-JP
  • PARK2
  • parkin
  • Parkinson disease (autosomal recessive, juvenile) 2, parkin
  • parkinson protein 2, E3 ubiquitin protein ligase (parkin)
  • PDJ
  • PRKN2_HUMAN
  • ubiquitin E3 ligase

Frequently Asked Questions

Pre‑test counseling covers the possibility of finding pathogenic, likely pathogenic, or variants of uncertain significance. Families should discuss the implications for treatment, prognosis, and family planning. Blood samples are taken, and results are interpreted by a clinical geneticist who explains inheritance patterns (autosomal recessive) and the need for parental testing if a child is affected.
Common early signs include mild tremor at rest, bradykinesia (slowness of movement), rigidity, and postural instability that appear before age 30. These symptoms often fluctuate and may improve with levodopa, but they can progress to more disabling motor deficits over time.
Patients with PRKN mutations usually develop symptoms in their 20s–30s and have a slower progression of motor symptoms. They often respond well to levodopa and may experience fewer motor complications early on, but they can still develop non‑motor symptoms such as cognitive decline later in the disease course.===
Currently, treatment focuses on symptom management with levodopa, dopamine agonists, and deep brain stimulation. No disease‑modifying therapy is approved specifically for PRKN mutations, but clinical trials of neuroprotective agents and gene‑therapy approaches are ongoing. Early initiation of levodopa often yields a better response and slower motor decline.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

Meyahealth

Ⓒ 2026. All rights reserved by MEYA

About UsTerms & PolicyFAQ